source
- Chutes & Ladders—Legend poaches Novartis vet to boost commercial potentialAfter former Legend Biotech CEO Ying Huang, Ph.D., left the company suddenly in July, Legend has found its permanent CEO, poaching Novartis veteran Ingrid Zhang as the CAR-T specialist eyes its nex…
- Novartis drops $125M for Sironax’s tech to cross blood-brain barrierNovartis stands alongside Big Pharma peers that have similarly invested in technologies to penetrate the blood-brain barrier, including GSK, Roche and Eli Lilly.BioSpace · 2mo ago↗ source
- Psychedelic therapeutics near first FDA approval as Compass Pathways and Definium report promising results